CD63 and lung carcinoma: This assay assesses EV membrane proteins related to the immune system, immune typing, chemoradiotherapy, vascular therapy (famitinib and anlotinib), and lung cancer, as well as the common EV protein markers CD63, CD81, and CD9 (15, 16).